Cwm LLC Buys 765 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Cwm LLC increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 69.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,870 shares of the biotechnology company’s stock after purchasing an additional 765 shares during the period. Cwm LLC’s holdings in Blueprint Medicines were worth $173,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of BPMC. Clearbridge Investments LLC bought a new position in Blueprint Medicines in the 2nd quarter valued at about $23,817,000. Dana Investment Advisors Inc. boosted its position in shares of Blueprint Medicines by 8.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 14,744 shares of the biotechnology company’s stock worth $1,589,000 after acquiring an additional 1,114 shares in the last quarter. Creative Planning boosted its position in shares of Blueprint Medicines by 27.1% during the 2nd quarter. Creative Planning now owns 12,351 shares of the biotechnology company’s stock worth $1,331,000 after acquiring an additional 2,636 shares in the last quarter. Algert Global LLC increased its stake in Blueprint Medicines by 81.0% in the second quarter. Algert Global LLC now owns 65,540 shares of the biotechnology company’s stock valued at $7,064,000 after acquiring an additional 29,330 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its position in Blueprint Medicines by 101.0% during the second quarter. Driehaus Capital Management LLC now owns 358,255 shares of the biotechnology company’s stock valued at $38,613,000 after purchasing an additional 180,043 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on BPMC. Needham & Company LLC reiterated a “buy” rating and issued a $130.00 price target on shares of Blueprint Medicines in a research note on Thursday, August 1st. Guggenheim lifted their target price on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Morgan Stanley raised their price target on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Finally, Barclays upped their price objective on shares of Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Insider Transactions at Blueprint Medicines

In related news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the transaction, the insider now owns 34,729 shares in the company, valued at $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Philina Lee sold 41,913 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Fouad Namouni sold 3,633 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Trading Down 2.4 %

Shares of BPMC stock opened at $84.40 on Thursday. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $121.90. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of -17.98 and a beta of 0.58. The stock has a 50-day moving average of $90.20 and a 200-day moving average of $98.76.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. The business had revenue of $138.20 million during the quarter, compared to the consensus estimate of $104.02 million. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company’s revenue for the quarter was up 139.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($2.19) EPS. On average, equities research analysts forecast that Blueprint Medicines Co. will post -3.99 earnings per share for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.